ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHA:600479)
China
· Delayed Price · Currency is CNY 11.22
+0.05 (0.45%)
At close: Mar 10, 2026
SHA:600479 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3,635 | 3,574 | 3,721 | 3,955 | 3,599 | Upgrade
|
| Other Revenue | - | 55.71 | 77.38 | 71.35 | 65.12 | Upgrade
|
| Revenue | 3,635 | 3,630 | 3,798 | 4,026 | 3,664 | Upgrade
|
| Revenue Growth (YoY) | 0.13% | -4.44% | -5.66% | 9.89% | 1.02% | Upgrade
|
| Cost of Revenue | - | 1,951 | 2,051 | 2,296 | 2,038 | Upgrade
|
| Gross Profit | 3,635 | 1,679 | 1,748 | 1,731 | 1,626 | Upgrade
|
| Selling, General & Admin | - | 1,138 | 1,167 | 1,172 | 1,128 | Upgrade
|
| Research & Development | - | 220.2 | 149.07 | 113.82 | 108.72 | Upgrade
|
| Other Operating Expenses | 3,194 | 25.8 | 38 | 37.93 | 35.11 | Upgrade
|
| Operating Expenses | 3,194 | 1,390 | 1,372 | 1,326 | 1,271 | Upgrade
|
| Operating Income | 440.51 | 288.57 | 376.42 | 404.85 | 354.6 | Upgrade
|
| Interest Expense | - | -1.11 | -1.67 | -2.21 | -2.11 | Upgrade
|
| Interest & Investment Income | - | 51.11 | 70.19 | 30.7 | 33.64 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.15 | -6.6 | -6.05 | -4.26 | -2.93 | Upgrade
|
| EBT Excluding Unusual Items | 438.36 | 331.97 | 438.9 | 429.08 | 383.19 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.63 | -1.6 | -1.3 | 4.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.05 | -0.94 | 0.17 | 33.11 | Upgrade
|
| Asset Writedown | - | -4.24 | - | - | - | Upgrade
|
| Other Unusual Items | - | 6.89 | 24.06 | 17.85 | 12.4 | Upgrade
|
| Pretax Income | 438.36 | 335.31 | 460.42 | 445.81 | 433.42 | Upgrade
|
| Income Tax Expense | 150.52 | 32.7 | 65.4 | 58.67 | 58.68 | Upgrade
|
| Earnings From Continuing Operations | 287.84 | 302.61 | 395.02 | 387.15 | 374.74 | Upgrade
|
| Minority Interest in Earnings | - | -71.85 | -74.61 | -84.64 | -72.68 | Upgrade
|
| Net Income | 287.84 | 230.76 | 320.41 | 302.51 | 302.06 | Upgrade
|
| Net Income to Common | 287.84 | 230.76 | 320.41 | 302.51 | 302.06 | Upgrade
|
| Net Income Growth | 24.74% | -27.98% | 5.92% | 0.15% | 1.68% | Upgrade
|
| Shares Outstanding (Basic) | 449 | 414 | 423 | 428 | 418 | Upgrade
|
| Shares Outstanding (Diluted) | 449 | 414 | 423 | 428 | 418 | Upgrade
|
| Shares Change (YoY) | 8.50% | -2.11% | -1.31% | 2.30% | -0.01% | Upgrade
|
| EPS (Basic) | 0.64 | 0.56 | 0.76 | 0.71 | 0.72 | Upgrade
|
| EPS (Diluted) | 0.64 | 0.56 | 0.76 | 0.71 | 0.72 | Upgrade
|
| EPS Growth | 14.97% | -26.43% | 7.32% | -2.11% | 1.69% | Upgrade
|
| Free Cash Flow | - | 351.45 | 399.13 | 699.04 | 413.69 | Upgrade
|
| Free Cash Flow Per Share | - | 0.85 | 0.94 | 1.63 | 0.99 | Upgrade
|
| Dividend Per Share | - | 0.360 | 0.350 | 0.350 | 0.600 | Upgrade
|
| Dividend Growth | - | 2.86% | - | -41.67% | -40.00% | Upgrade
|
| Gross Margin | 100.00% | 46.25% | 46.02% | 42.98% | 44.38% | Upgrade
|
| Operating Margin | 12.12% | 7.95% | 9.91% | 10.05% | 9.68% | Upgrade
|
| Profit Margin | 7.92% | 6.36% | 8.43% | 7.51% | 8.24% | Upgrade
|
| Free Cash Flow Margin | - | 9.68% | 10.51% | 17.36% | 11.29% | Upgrade
|
| EBITDA | 516.7 | 364.76 | 457.17 | 473.88 | 418.84 | Upgrade
|
| EBITDA Margin | 14.22% | 10.05% | 12.04% | 11.77% | 11.43% | Upgrade
|
| D&A For EBITDA | 76.19 | 76.19 | 80.74 | 69.03 | 64.24 | Upgrade
|
| EBIT | 440.51 | 288.57 | 376.42 | 404.85 | 354.6 | Upgrade
|
| EBIT Margin | 12.12% | 7.95% | 9.91% | 10.05% | 9.68% | Upgrade
|
| Effective Tax Rate | 34.34% | 9.75% | 14.21% | 13.16% | 13.54% | Upgrade
|
| Revenue as Reported | - | 3,630 | 3,798 | 4,026 | 3,664 | Upgrade
|
| Advertising Expenses | - | 12.82 | 10.56 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.